| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to appraisal by NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer |
|
Medicine details |
|
| Medicine name | topotecan (Hycamtin®) |
| Formulation | capsule |
| Reference number | 315 |
| Indication | Monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate |
| Company | GlaxoSmithKline |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/11/2008 |
| NICE guidance | TA184: Topotecan for the treatment of relapsed small-cell lung cancer |